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Summary
A CpG island DNA methylator phenotype has been postulated to explain silencing of the hMLH1 DNA mismatch repair
gene in cancer of the microsatellite mutator phenotype. To evaluate this model, we analyzed methylation in CpG islands
from six mutator and suppressor genes, and thirty random genomic sites, in a panel of colorectal cancers. Tumor-specific
somatic hypermethylation was a widespread age-dependent process that followed a normal Gaussian distribution. Because
there was no discontinuity in methylation rate, our results challenge the methylator phenotype hypothesis and its hypotheti-
cal pathological underlying defect. We also show that the mutator phenotype dominates over the gradual accumulation
of DNA hypermethylation in determining the genotypic features that govern the phenotypic peculiarities of colon cancer
of the mutator pathway.
Introduction nonpolyposis colorectal cancers (HNPCC) and sporadic gastro-
intestinal tumors (Kolodner and Marsischky, 1999). Some of
these MSI-positive cancers undergo epigenetic silencing of theThe accumulation of genetic alterations during tumorigenesis
substantiates the mutational theory of cancer (Loeb, 1991), but DNA MMR gene hMLH1, a process that is accompanied by
hypermethylation of the gene’s promoter (Kane et al., 1997).epigenetic alterations are also germane to carcinogenesis
(Jones and Laird, 1999). Evolution by natural selection has de- The existence of a CpG island methylator phenotype (CIMP)
has been postulated to explain the somatic hypermethylationveloped epigenetics as a means to efficiently achieve the regu-
lated fluctuations in gene expression that govern cell differentia- associated with silencing of the hMLH1 mutator gene and sev-
eral tumor suppressor genes (Ahuja et al., 1997; Toyota et al.,tion and development. This process has been called the
epigenetic code (Breivik and Gaudernack, 1999) or histone code 1999a).
The CIMP has been proposed to be responsible for the(Jenuwein and Allis, 2001; Turner, 2002). In a highly interrelated
and complex process, posttranslational modifications in his- manifestation of the microsatellite mutator phenotype (MMP)
characteristic of tumors with MSI (Toyota et al., 1999a; Toyotatones and other chromatin proteins, together with changes in
DNA methylation at CpG sequences, lead to changes in gene and Issa, 2000). MSI-positive tumors display a mutator pheno-
type characterized by an over two orders of magnitude higherexpression and permanent silencing (Bird, 2001; Baylin and
Bestor, 2002). mutation rate than normal cells (Ionov et al., 1993; Shibata et
al., 1994). The MMP leads to the accumulation of oncogenicSomatic hypomethylation and hypermethylation have been
associated with tumorigenesis. Global hypomethylation occurs mutations in cancer genes (oncogenes and tumor suppressors),
ultimately leading to cancer (Perucho, 1996; Kinzler and Vo-in human tumors (Feinberg and Vogelstein, 1983) and can either
suppress (Laird et al., 1995) or induce (Eden et al., 2003) tumors gelstein, 1996).
The MMP is a critical determinant of the fate of the tumor cellin mice. Hypermethylation has been linked to tumor suppressor
gene silencing (Jones and Baylin, 2002). Perhaps the best exam- and drives tumorigenesis through a defined pathway (Perucho et
al., 1994; Perucho, 1996; Olschwang et al., 1997; Breivik etple is the silencing of hMLH1 DNA mismatch repair (MMR) gene
in colon cancer. al., 1997). Mutator genes are therefore more fundamental than
oncogenes and tumor suppressor genes, as the former causeAbout 13% of unselected colon tumors accumulate hun-
dreds of thousands of somatic mutations in microsatellite se- mutations that trigger the oncogenic potential of the latter. Can-
cer driven by mutator genes represents a “remote control”quences (Ionov et al., 1993). MMR deficiency underlies this
genome-wide microsatellite instability (MSI) in some hereditary mechanism for carcinogenesis, as mutator gene inactivation
S I G N I F I C A N C E
Silencing of hMLH1 in tumors of the microsatellite mutator phenotype illustrates the importance of epigenetics in cancer. The bimodal
distribution of ubiquitous microsatellite mutations defines the microsatellite mutator phenotype, a critical determinant of tumor cell
fate driving tumorigenesis through a specific pathway. The methylator phenotype hypothesis, as begetting the microsatellite mutator
phenotype, adds a more fundamental earlier step in carcinogenesis. However, our evidence for the absence of a bimodal distribution
for somatic hypermethylation is conclusive since it was obtained by an unbiased approach. The epigenetic origin of the mutator
phenotype, and cancer, remains fascinating and mysterious. However, it is not initiated by a punctual event underlying a pathogenic
methylator phenotype, but rather by a gradual age-dependent disintegration of the epigenetic code.
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does not immediately lead to altered cell growth or survival which of the tumors induce methylation with rates higher than
normal cells and which ones do not (Figure 1C). However, be-(Perucho et al., 1994; Perucho, 1996; Cahill et al., 1999).
The sequence of events in the MMP pathway for cancer cause the number of loci analyzed was very small, it was possi-
ble that a distinctive group of tumors could contain none orcan be summarized as follows: inactivation of MMR (mutator)
genes causes a mutator phenotype, which causes oncogenic very few methylation alterations (Figures 1B and 1C).
To directly address this possibility, we analyzed the globalmutations, which cause cancer. The implicit sequence of events
in the methylator phenotype “ultra remote control” pathway for methylation pattern in 32 colorectal cancer specimens by meth-
ylation-sensitive amplified fragment length polymorphism (MS-cancer is as follows: CIMP causes inactivation of MMR, which
causes the MMP, which causes oncogenic mutations, which AFLP). The technique permits the unbiased analysis of the meth-
ylation status of a random subset of CpG sequences throughoutcause cancer (Toyota et al., 1999a). Methylator phenotype is
thus even more fundamental than mutator phenotype for cancer the genome (Yamamoto et al., 2001). In these particular experi-
ments, we scanned the status of the two CpG sites containedpathogenesis, as it generates the MMP in tumors not carrying
germline and/or somatic MMR mutator mutations. in the NotI restriction endonuclease methylation-sensitive rec-
ognition site (GCGGCCGC). In MS-AFLP fingerprinting, tumor-Despite its importance, the CIMP concept has not been
precisely defined. The current definition rests on the simultane- specific somatic hyper- and hypomethylation are recognized as
differences of band intensity between PCR products derivedous tumor-specific hypermethylation of multiple CpG islands.
The CIMP conceptually parallels the MMP that was defined by from normal and tumor DNA (Figure 2).
About 100 bands appeared in each experiment. Of these,the presence of ubiquitous somatic mutations in mononucleo-
tide repeats (Ionov et al., 1993). But the MMP was defined about 75 were universally amplified from normal tissue DNA
(Figure 2). Nine of eleven such bands, characterized by cloningprecisely because the majority of the tumors did not contain
these mutations. The bimodal distribution of microsatellite mu- and sequencing, matched human sequences derived from the
Human Genome Project through BLAST search. Only one oftations allowed the segregation of colon tumors into tumors with
and tumors without these ubiquitous microsatellite mutations the NotI sites in the nine characterized sequences was not inside
a well-defined CpG island according to the currently accepted(Ionov et al., 1993; Perucho et al., 1994).
The methylator phenotype hypothesis also necessarily im- criterion (Gardiner-Garden and Frommer, 1987).
plies a clear-cut distinction between tumors with and tumors
without an enhanced pathological rate of somatic DNA hyper- Hypermethylation and hypomethylation in colon cancer
About 40% of all CpG sequences analyzed in these experimentsmethylation. This segregation is necessary to postulate that
some tumors possess a methylator phenotype, similar to the exhibited methylation alterations. Hyper- and hypomethylation
were each observed in about 30 of the 75 bands (40%) withmutator phenotype possessed by tumors of the MMP. The
methylator phenotype concept is important because it implies a 20% overlapping (six bands showing both hyper- and hypo-
methylation in different tumors). The average level of hyper-an underlying defect in the cellular machinery responsible for
the generation of hypermethylation events, similar to the MMR methylation in the 32 tumors analyzed was 21.5% (203 hyper-
methylated bands of 944 total analyzed bands) while thedeficiency underlying MSI and the MMP (Laird, 2003). We car-
ried out this study to test this hypothesis. We analyzed the hypomethylation average was 10.2% (108 of 1056 total analyzed
bands). The average number of altered bands per tumor washypermethylation alterations occurring in CpG islands in some
cancer genes (mutators and suppressors) and random genomic 6.34 for hypermethylation and 3.3 for hypomethylation. There
was no correlation between hypermethylation and hypomethyl-sites, in a panel of colorectal tumors with and without MSI. The
results show that tumor-specific somatic hypermethylation is a ation. Although tumors with levels of hypermethylation higher
than average had a higher level of hypomethylation, and vicewidespread phenomenon shared by all colon tumors and that
the alterations are dispersed into a nearly perfect normal versa, the differences were not significant (data not shown).
In this report, we focus on hypermethylation and we will notGaussian distribution when a sufficient number of loci are ana-
lyzed. We also show that the MSI phenotype is dominant over further elaborate on hypomethylation. The methylation status
of 30 bands showing tumor-specific hypermethylation is sum-the CpG island methylation phenotype.
marized in Figure 3A. Some bands without methylation changes
(positions 5 and 17 of Figure 3A top panel and the last twoResults
positions in bottom panel) were included in this analysis because
they exhibited alterations in a parallel analysis of 20 gastricHypermethylation of cancer genes and anonymous
CpG islands cancers. Bands with no methylation alterations in colon and
gastric cancers were excluded. Some bands exhibited moreWe examined by methylation-specific PCR (MSP) (Herman et
al., 1996) the promoters of six genes in a panel of 207 colorectal alterations than others (top panel), but the alterations were dis-
cancers and the corresponding paired normal tissue. These persed gradually among the colon tumors (bottom panel). The
included the MMR mutator gene hMLH1, the O6MGMT DNA results with the gastric cancers analyzed were similar (data not
repair gene, and the tumor suppressor genes p16INK4A, p14ARF, shown).
APC, and CDH1 (E-cadherin) (Figure 1A). All of these genes
undergo hypermethylation in colon cancer (Toyota et al., 1999a; Distribution of genetic and epigenetic somatic
alterationsEsteller et al., 2001; Shen et al., 2003). A diagram of the tumor
arrangement based on the number of methylated loci per tumor Figure 3B shows the effect of increasing the number of loci
analyzed in the shape of the distribution of methylation alter-formed a gradual pattern rather than a bimodal distribution (Fig-
ure 1B). These results are not compatible with the CIMP hypoth- ations in the tumors. Analysis of only 5 loci was ambiguous,
with a gradual diminishing of tumors containing multiple methyl-esis since it is not possible to decide with a sound criterion
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Figure 1. Gradual distribution of CpG island DNA methylation alterations in colon cancer
A: Representative MSP experiments for methylation analysis of hMLH1 and p16 genes. PCR products amplified with unmethylated (U) and methylated (M)
sequence-specific primers. Untreated DNA is a negative control in which the sodium bisulfite treatment was omitted. MW: DNA fragment ladder used as
molecular weight marker.
B: Summary of CpG hypermethylation. Upper: Methylation status of six CpG islands from known suppressor/mutator genes as well as an anonymous CpG
island (ACG) identified through MS-AFLP (see Figure 2) in 207 colorectal cancers (filled: methylated, blank: unmethylated). Microsatellite instability (MSI) is
indicated at the top row (filled, MSI-positive, blank, MSI-negative). The cut off points for the grouping of tumors into two groups with relatively high and
low methylation alterations are indicated (see text).
C: The methylated loci per tumor from the above data show a nonbimodal distribution. MSI-positive tumors were also evenly distributed.
ated loci (Figure 3B, top), similar to the curve of the functional the tumors with from the tumors without abundant microsatellite
mutations.loci (Figure 1C). However, when more loci were analyzed, the
distribution profile acquired a distinctive Gaussian shape, re-
flecting a normal distribution of random events (Figure 3B, lower Methylator versus mutator genotype-phenotype
panels). No single tumor remained without methylation alter- relationships
ations after all 35 loci were considered. Therefore, tumor-spe- We next compared the genotypic features of colon tumors with
cific somatic hypermethylation is a widespread and gradual respect to their mutator and ‘methylator’ phenotypes. We di-
phenomenon. In contrast, the distribution of microsatellite muta- vided the tumors according to the methylation status of the
tions was distinctively bimodal, regardless of the number of loci CpG islands analyzed by MSP (Figure 1B), into a group with
analyzed (Figure 3B). two or more methylated CpG islands and another with one or
none (criterion 1). This is a division at approximately the medianThus, there is a fundamental difference between the tumor-
specific accumulation of CpG methylation alterations and micro- value for methylation (1.5 methylated loci per tumor). The results
showed a significant association between methylation and rightsatellite mutations. The methylation alterations distributed grad-
ually, without a defined boundary (Figure 3A). Mutations in side location (Figure 4A). Comparison of tumors with no methyl-
ation alterations with those with more than 2 alterations (criterionmicrosatellite sequences exhibited on the other hand a discon-
tinuous distribution of (Figure 3C), with a sharp border splitting 2), that resembles the comparison of lower and higher quartiles
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prototypical in colorectal tumorigenesis, K-ras oncogene and
APC and p53 tumor suppressors (Figure 4B).
Comparison of the genetic and epigenetic alterations in re-
gard to tumor cell phenotype revealed that the mutator pheno-
type and the genetic alterations (MSI) were dominant over the
“methylator phenotype” and the epigenetic alterations (CpG
island methylation). The differences in genotype and phenotype
observed between MSI-positive and-negative tumors were in-
dependent on CpG island methylation status (Figure 4D). On
the other hand, filtering out the MSI-positive cases from the
population of tumors diminished the asymmetries between rela-
tively high and low CpG island methylation in stage and grade,
and K-ras and p53 mutations (Figure 4C). Therefore, while tu-
mors with and without the MMP exhibited marked differences
in genotype and phenotype, tumors with relatively high and low
CpG island DNA methylation were essentially indistinguishable.
The preferential location in the proximal colon was shared
by DNA hypermethylation and MSI, with the latter showing an
even more pronounced tendency (Figure 5). The only significant
feature of DNA hypermethylation that was not shared with MSI
was its association with older age. The methylation of each CpG
island in particular, and the average of all the CpG islands,
increased with the patients’ age (Figure 6).
Discussion
Since the methylator concept was proposed in colon cancer
(Ahuja et al., 1997; Toyota et al., 1999a), this hypothesis has
received considerable attention, and the CIMP is currently re-
garded as the determining event driving a particular carcinogen-
esis pathway (Toyota et al., 1999a; Toyota and Issa, 2000; Elsa-
leh et al., 2000; Peltomaki et al., 2000; Baylin and Bestor, 2002;
van Rijnsoever et al., 2002; Iacopetta, 2003). The CIMP has also
been assigned to various types of tumors other than colorectal
cancer. So far, the CIMP has been reported in neoplasms of
stomach (Toyota et al., 1999b), pancreas (Ueki et al., 2000),
ovary (Strathdee et al., 2001), hepatocellular carcinoma (Shen
et al., 2002), and adenoma (Rashid et al., 2001), as well as
Figure 2. DNA hypermethylation in colon cancer detected by MS-AFLP DNA hyperplastic polyp-polyposis (Chan et al., 2002) of the large
fingerprinting intestine. Two groups have recently reported the absence of
Autoradiogram of a MS-AFLP fingerprint of colon tumors with and without evidence supporting the CIMP model. One group interpreted
MSI. Two different amounts of template DNA (10 and 15 ng) were amplified their data as not supporting the CIMP hypothesis in esophageal
for each sample. Left empty arrowheads represent hypomethylation,
adenocarcinoma (Eads et al., 2001) and another group reportedwhereas right solid arrowheads indicate hypermethylation. Asterisks denote
data inconsistent with the CIMP in colorectal cancer, althoughbands exhibiting recurrent hypo- or hypermethylation in several tumors, with
the most common alterations highlighted by double asterisks. N: normal, T: the results were not explicitly interpreted as contradicting the
tumor DNA. Additional altered smaller bands were detected in the same CIMP hypothesis (Hawkins et al., 2002).
experiment by shorter electrophoresis.
The definition of the CIMP has been in constant evolution
since its inception (Toyota et al., 1999a, 1999b, 2000; Ueki et
al., 2000; Shen et al., 2002, Rashid et al., 2001; Chan et al.,
2002). Initially the concept was defined by the “frequent concor-
(Figure 1B), yielded similar results (data not shown). No signifi- dant methylation of the type C clones examined” (Toyota et al.,
cant associations were observed with the rest of the parameters 1999a). The CIMP-positive group was classified as having a
analyzed (gender, progression, differentiation, K-ras or p53 mu- high level of type C methylation (three or more loci) (Toyota et
tations). al., 1999a). Subsequently, the CIMP has been diversely charac-
On the other hand, MSI positive tumors presented significant terized from a methylation tendency (Peltomaki et al., 2000) to
differences compared to MSI negative tumors, in accord with a variable pattern of hypermethylation of CpG islands in tumor
our previous findings (Ionov et al., 1993; Yamamoto et al., 2002). suppressor genes (Shen et al., 2002). The current common
MSI positive tumors were predominantly found in the proximal definition of simultaneous methylation of multiple CpG islands
colon, were less advanced in tumor progression, and many is not very precise. The issue is further complicated because
exhibited a poorly differentiated phenotype. MSI positive tumors tumors were classified into two distinct categories (CIMP and
CIMP) only in the first report of colorectal tumors (Toyota etalso displayed a low mutational incidence in the cancer genes
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Figure 3. DNA hypermethylation follows a normal distribution in contrast with the bimodal distribution of MSI
A: DNA hypermethylation is gradual in colon cancers. The methylation status of 30 NotI CpG sites analyzed by MS-AFLP is shown. The five loci analyzed by
MSP are also included. In the top panel, the 35 CpGs (each lane) are ordered in an unbiased manner according to the size of the MS-AFLP fingerprint
band. The five MSP loci are evenly distributed after every five loci. In the bottom panel, the 35 CpG loci and the 32 colorectal cancers are sorted out by
decreasing methylation frequency.
B: The distribution of CpG epigenetic alterations is dependent on the number of loci analyzed, in contrast with the independency of MSI-genetic alterations.
The tumors are distributed by percentage of methylated and mutated loci analyzing 5 (top) to 35 (bottom) CpGs. The microsatellite markers are also
distributed in groups of five. The DNA methylation data is derived from the top panel of Figure 3A and the mutation data from Figure 3C. The first five loci
in this panel correspond to the first 5 CpGs and the first 5 microsatellite markers at the left in panel A top and panel C, respectively. Scale on the X axis:
0  tumors with no hypermethylation or mutation (0%); 0.2  tumors with one or more loci altered up to 20%; 0.4  tumors with more than 20% up to 40%
loci altered, and so on. P values were obtained from the statistical comparison of observed values with those predicted for a normal distribution.
C: MSI is discontinuous in colon cancer. The extent of MSI was analyzed using 25 microsatellite markers (5 mononucleotide and 20 dinucleotide markers)
in 61 colorectal cancer specimens, which are sorted out by mutation frequency.
al., 1999a). In almost all subsequent publications (Toyota et al., (Ueki et al., 2000; Rashid et al., 2001; Shen et al., 2002, 2003;
van Rijnsoever et al., 2002; Chan et al., 2002).1999b; Ueki et al., 2000; Shen et al., 2002; Rashid et al., 2001;
Chan et al., 2002), additional groups such as CIMP-I (intermedi- Our data with colon (Figures 1 and 3) and gastric (not shown)
cancer, as well as the data from others (Eads et al., 2001;ate) or CIMP-L (low) were used to embrace tumors with interme-
diate levels of methylation. Despite these difficulties, the classi- Hawkins et al., 2002; Shen et al., 2002, 2003), show that it is
impossible to draw a precise borderline between CIMP-positivefication of CIMP-positive tumors is usually done by selecting
tumors with 2–3 altered genes of the commonly used 3–6 loci. and -negative tumor groups due to the gradual distribution pat-
tern of CpG island somatic hypermethylation, which is far fromThis is arbitrary, as recognized by the same authors of these
reports (Shen et al., 2002; van Rijnsoever et al., 2002). Neverthe- the bimodal distribution reported in the original paper (Toyota
et al., 1999a). The reason for this discrepancy might partly restless, the CIMP model remains generally supported even when
the experimental data appears inconsistent with the concept on the criterion that originated the CIMP in the initial report.
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Figure 4. Genetics, but not epigenetics, underlies colon cancer clinicopathological features
A: CpG island methylation associates to proximal location but not to any of the other phenotype parameters. Tumors with weak methylation (CIMP)
were compared with those with intense methylation (CIMP) using the MSP data from the 207 cases. Numbers on bars represent the actual number of
cases, and p values less than 0.05 are highlighted. The borderline between CIMP and CIMP was derived by criterion 1 elaborated in Figure 1. Criterion
2 also yielded similar results, with only the site showing significant right side predominance (p  0.00001). The MSI/CIMP relationship also remained significant
(p  0.004).
B: Mutator phenotype exhibits strong associations with many parameters, including right side preference. The panel demonstrates the results from the 207
cases used for the MSP analysis. The distribution of MSI-positive/negative tumors regarding tumor progression was 3/11 (21%); 12/57 (17%); 11/63 (15%); 1/35
(2.7%); and 0/5 (0%) for Dukes’ A:B:C:D: liver metastases, respectively (p  0.024 2 test for trends). Results obtained from a larger tumor sample for which
the MSI status has been previously determined (Malkhosyan et al., 2000) showed that the significant associations of MSI-positive tumors extended to gender
(female predominance, p  0.0017); to Dukes’ stage (nonmetastatic predominance, p  0.003); and K-ras (wild-type predominance, p  0.0001). APC
suppressor gene mutations were also analyzed in a subset of tumors with a significantly lower mutational incidence in MSI-positive cancers (14 APC mutant
and 36 wild-type in MSI-positive tumors versus 36 APC mutant and 37 wild-type in MSI-negative tumors, p  0.017).
C: CIMP does not differentiate among colon cancers. MSI-positive cases were eliminated from the analysis.
D: MSI is dominant over CIMP. MSI-positive and MSI-negative tumors were compared using only cases with intense methylation (CIMP) according to
criterion 1 (Figure 1).
Analysis of individual CpG islands (not shown) showed that methylation of hMLH1 correlated with right side (p  0.0004) and female predominance (p 
0.06), old age (p 0.003), poorly differentiated histological phenotype (p 0.0002), and low mutational incidence at K-ras and P53. Similarly, p16 methylation
correlated with right side, poorly differentiated phenotype, and methylated p14 and MGMT exhibited right side predominance. These characteristics
overlapped with the features of MSI-positive colon cancer. Except right side location, these differences lost their statistical significance in multiple regression
analysis and univariate analysis after MSI-positive tumors were eliminated (not shown).
Mutation analysis for K-ras and p53 was performed as previously described (Ionov et al., 1993; Yamamoto et al., 1997, 1999). Somatic APC mutations (from
codons 865 to 1590, comprising the mutation cluster region in exon 15) were identified and characterized by SSCP and sequencing of normal-tumor DNA
as described (Yamamoto et al., 1997, 1999). p values were calculated by Fisher’s exact test or Chi square with Yates correction.
The CIMP concept was reached after selecting particular on whether methylation could be detected in normal tissues,
while the semiquantitative method utilized for detection was nottypes of CpG islands showing methylation, those denominated
class C or cancer specific. Class A, or age-specific, CpG islands very sensitive (Toyota et al., 1999a; Shen et al., 2002, 2003). A
CpG island showing a faint band in the MSP experiments fromwere excluded from the analysis (Toyota et al., 1999a). However,
the distinction of class A from class C CpG islands depended the normal tissue DNA was classified as belonging to class A,
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Figure 5. Gradient of CpG island DNA methyla-
tion and MSI in colon cancers in the large in-
testine
The tumors are classified for CIMP according to
criterion 1 (Figure 1).
but another CpG island failing to reveal a band was classified CpG islands, and they follow a gradual distribution regarding
their presence and detectability in normal tissues. Furthermore,as class C. However, the CpG islands initially classified as type
C have been subsequently shown to be methylated in normal a CpG island that is classified as class C in one type of tumor
is classified as class A in another type of tumor (Eads et al.,tissues when the sensitivity of the detection assays was in-
creased (Kuismanen et al., 1999; Shen et al., 2003). Moreover, 2001; Ueki et al., 2000). But if there is hypermethylation of a
particular CpG island in any normal tissue, this means that it isthese class C loci also have been found to have a tight connec-
tion with aging, which was a peculiarity of the class A CpG not cancer specific. The restriction of some class C CpG islands
to a particular tumor type would lead to the enigmatic conceptislands (Kuismanen et al., 1999; Malkhosyan et al., 2000; Shen
et al., 2003; this work). In other words, a class C CpG island is of a tissue-specific and tumor-specific methylator phenotype.
Therefore, the CIMP has become a convoluted, ambiguous, andno more than a disguised class A CpG island.
There is no clear boundary between class A and class C untenable concept. The contradictory nature of what CIMP has
Figure 6. Age is the only parameter where DNA hypermethylation is independent of MSI status
A: Average ages of each patient group of the 207 tumor cohort (Figure 4) were compared by Student’s t test.
B: The 207 patients were divided into seven groups according to age with a 10 year interval. The average of methylated loci per tumor (percentage of
the seven loci) was plotted for each age group.
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become can be exposed by the statement that the cancer- to hMLH1 silencing and this is linked to its hypermethylation. But
the determinant genotypic feature that propels the phenotypicspecific hypermethylator phenotype can also occur in normal
tissue (Peltomaki et al., 2000). differences of colorectal cancer is MSI and mutator phenotype
and not CpG island hypermethylation and methylator phenotypeThe data from Figure 3 imply that up to 40% of all genomic
CpG islands undergo hypermethylation in some colon cancers. (Figure 4). Our results show that differences in genotype and
phenotype (K-ras and p53 mutations, differentiation and pro-This extrapolation is based on the unbiased nature of the NotI
sites analyzed by MS-AFLP DNA fingerprinting (Yamamoto et gression) are independent of the status of CpG island methyla-
tion (Figure 4D). On the other hand, if MSI-positive cancers areal., 2001) and the calculation that the vast majority (80%) of
NotI sites are located in CpG islands (Kutsenko et al., 2002). eliminated, the remaining tumors with higher DNA methylation
were indistinguishable from the group of tumors with lowerThe last premise for such an extrapolation is that there are no
structural or functional differences between CpG islands with methylation, regardless of the criteria for their segregation (Fig-
ure 4C).and without NotI sites. In this line, other different NotI sites
amplified with different primer/adaptor combinations also have The distinctive features that MMP tumors display compared
with tumors without MSI is due to the particular spectrum ofsimilar levels of hypermethylation (unpublished observations).
Therefore, if hypermethylation were due to defects in transacting mutated cancer genes in MSI-positive tumors (Markowitz et
al., 1995; Rampino et al., 1997; Lindblom, 2001). MMP tumorsfactors required for the protection of CpG islands from en-
croaching methylation (Laird, 2003), individual “universal” trans- display a low incidence of mutations in the APC and P53 tumor
suppressor genes and K-ras oncogene, prototypical for colonacting factors would be required to cover a significant fraction
of all the genomic CpG islands. Therefore, it is more likely that cancer (Ionov et al., 1993; Perucho et al., 1994; Kim et al., 1994;
Olschwang et al., 1997; Breivik et al., 1997). Instead, MSI-posi-the methylation changes (both hyper- and hypomethylation) rep-
resent frequent and accumulative stochastic fluctuations (Laird, tive colon tumors carry a plethora of different mutated genes,
such as TGFßRII and Bax, which are rarely found in MSI-negative2003) occurring prior to and/or during tumorigenesis.
Many of these individual random CpG sequences were hy- tumors (Markowitz et al., 1995; Rampino et al., 1997; Woerner
et al., 2003). This is because in a MMR deficiency background,permethylated in a majority of the colon and gastric tumors (six
different MS-AFLP bands were each hypermethylated in over mutations occur preferentially in genes with simple repeats in
their coding or regulatory sequences (Perucho, 1996; Suzuki et50% of the tumors, Figure 3A and data not shown). The results
also imply that widespread CpG island hypermethylation often al., 2002). The differences in genotype can explain the differ-
ences in phenotype displayed by MMP tumors, such as poorlyaffects the same genomic loci in tumorigenesis. Therefore, if
different defects were to lead to hypermethylation of distinct differentiated histological features, a less advanced stage of
tumor progression, and a better survival (Ionov et al., 1993;groups of structurally similar CpG islands (Laird 2003), this
would require the concomitant existence in each tumor of sev- Thibodeau et al., 1993; Boland et al., 1998; Elsaleh et al., 2000).
The anatomical distribution of MSI tumors overlaps the pref-eral defective methylator genes. The results obtained by unsu-
pervised clustering that show groups of tumors with high and erential localization of hypermethylation in the proximal colon
(Figures 4 and 6). The reason for the exacerbated asymmetrylow levels of concordant methylation (Yan et al., 2002) can be
better explained by arbitrary ordering of the clustered tumors in anatomical location for both mutator and methylator pheno-
types is intriguing. HNPCC tumors also show a preferentialand arbitrary selection of subclusters of CpG islands.
Nevertheless, even though no CIMP underlies the common localization in the proximal region of the large bowel, although
the disparity (about 70%) (Kuismanen et al., 2000) is not sosomatic methylation alterations observed in many tumors, there
is an unequal distribution of methylation alterations following remarkable as in sporadic tumors (about 90%) (Kuismanen et
al., 2000; Figure 4).an increasing gradient from the distal to proximal colon (Figure
5). Another critical variable is the age. Methylation of all CpG The preferential proximal colon location of both MSI-positive
tumors and CpG island methylation tumors could be due to anislands analyzed in colorectal cancer demonstrated an inclina-
tion toward older age (Figure 6). Together with other reports intrinsic asymmetry in some critical cellular processes between
proximal and distal colon, such as stem cell renewal and mitotic(Kuismanen et al., 1999; Wiencke et al., 1999; Malkhosyan et
al., 2000; van Rijnsoever et al., 2002; Shen et al., 2002), these activity (Lipkin et al., 1962; Potten et al., 1992). A higher mitotic
activity may be sufficient to increase the probability of occur-results show that hypermethylation of most CpG islands is a
process strongly age dependent in gastrointestinal tumorigene- rence of both mutator mutations (somatic structural alterations
inactivating MMR genes) and epigenetic silencing of hMLH1,sis. Thus, proximal colon cancers in old patients have more
methylation than distal cancers in young patients (Figure 5). and more importantly, the necessary additional cell replications
before neoplastic transformation can eventually occur (Ionov etThe reason underlying this distortion remains mysterious,
but it implies a disintegration of the epigenetic code during al., 1993; Perucho et al., 1994; Perucho, 1996; Tsao et al., 2000).
The age dependence of MSI-positive tumors with hMLH1 meth-aging in tissues with high cell turnover. However, to assign a
methylator phenotype to the increased gradient of methylation ylation is also consistent with this hypothesis. The difference in
incidence of MSI-positive proximal tumors between hereditaryin the proximal colon of old cancer patients (from whatever
unknown reasons) would be equally inadequate as to assign a and sporadic cases could be explained by the lower depen-
dence of the hereditary cancers on mitogenesis, as these can-mutator phenotype to a concentration gradient of carcinogens
causing mutations at p53 in the distal colon (Breivik and Gauder- cers have a shortened pre-neoplastic period due to the germline
mutations.nack, 1999).
DNA hypermethylation at multiple loci correlates with MSI- This hypothesis predicts that MSI-positive tumors with low
methylation will be also preferentially found in the proximal colonpositive colon cancer (Figure 4A). This is because many tumors
with MSI, especially sporadic cases, owe the mutator phenotype regardless of their hereditary or nonhereditary origins. Our data
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microsatellite repeats, including mono- and dinucleotide repeats (the list ofare consistent with this hypothesis although corroboration with
the loci and PCR primer information available upon request). Up to 30% ofa larger sample is needed: 7 MSI-positive/51 MSI-negative prox-
the tumors shifted from MMP negative to the category of MSI-L (as definedimal versus 1 MSI-positive/64 MSI-negative distal (p  0.020)
by the Bethesda Criteria of tumors with at least one and no more than 40%
in the CIMP-negative group and 18/36 versus 1/22 in the CIMP- mutated microsatellite markers) after analysis of 75 dinucleotide markers.
positive group (p  0.007; Figure 4D). We extrapolated that all tumors would fall into the MSI-L category after
The reason for the age-dependent silencing and hypermeth- analysis of 200–250 dinucleotide repeats. Therefore, MSI-L cancers were
grouped together with the MMP-negative.ylation of hMLH1 remains to be elucidated. However, the appar-
ent lack of association of MSI with aging is explained by the
Methylation-specific PCR (MSP)heterogeneous mixture of familial and sporadic tumors in unse-
MSP was carried out based on the original method developed by Hermanlected colorectal cancer series. Familial cancers occur in
et al. (1996) with minor modification. Five hundred nanograms to one micro-
younger patients while silencing and methylation in older tumor gram of genomic DNA were subjected to sodium bisulfite treatment, then
patients, and the two extremes neutralize each other (Malkho- purified using Wizard DNA Clean-Up system (Promega) and stored at20C.
syan et al., 2000). After bisulfite treatment and subsequent purification, DNA was amplified
separately using specific primers for unmethylated and methylated genomicWhile age dependence and anatomical localization are MMP
sequences. We used the published MSP primers and identical annealingindependent, the genotype and phenotype features of colon
temperatures for hMLH1 (Yamamoto et al., 2001), p16 (Herman et al., 1996),cancers with MSI supersede those displayed by the high hyper-
p14 (Shen et al., 2003), MGMT (Esteller et al., 1999), promoter 1A of APC
methylation tumor group. There is no clear explanation for the (Tsuchiya et al., 2000), and CDH1 (Graff et al., 1997, Island 3). Primers for
association of MSI and CpG methylation with gender (Breivik an anonymous CpG island (ACG) identified by MS-AFLP were designed
et al., 1997; Malkhosyan et al., 2000; Elsaleh et al., 2000), and based on the BLAST search data (GenBank AC008425). The sequences for
unmethylated-specific primers were 5-GGGTTTGGGTAAATTTGTTGTTT-3environmental and genomic factors may play roles. However,
(nt 7733–7755) and 5-AATCAAACACATCTCACA-3 (nt 7879–7862), whichanatomical location, gender, and age preempt cancer develop-
amplify a 147 bp PCR product. For the methylated-specific reaction, thement and fall beyond cancer cell genotype-phenotype relation-
primer sequences were 5-TGGGTAAATTCGTCGTTC-3 (nt 7738–7735) andships.
5-ATCAAACGCATCTCGCGA-3 (nt 7878–7861), which amplify a 141 bp
In conclusion, after its manifestation, the microsatellite mu- product. The annealing temperature for the ACG primers was set at 58C. A
tator phenotype appears to determine the fate of the tumor total of 10 l PCR mixture consisted of 1 l bisulfite-treated DNA, 1 PCR
cell and to be dominant over the age-dependent epigenetic buffer (16.6 mM of ammonium sulfate, 67.0 mM of Tris-HCl, 6.7 mM of
magnesium chloride, and 10 mM of 2-mercaptoethanol), 0.4 mM dNTP, 0.5alterations that may originate the mutator phenotype itself. Thus,
M each primer, and 0.25 unit of Platinum Taq polymerase (Gibco BRL,there are two distinct groups of colon cancers defined by the
Rockville, Maryland). The amplification was started at 95C for 5 min, followedpresence or absence of MSI and the underlying MMP. Whether
by 35 cycles of 95C for 30 s, various annealing temperature (58C –65C) forthe MSI-negative tumors can be subdivided into two classes
30 s, and 72C for 30 s, and finished with 8 min of final extension at 72C.
depending upon their degree of epigenetic alterations remains The PCR products were loaded on a 2.0% agarose gel and visualized under
to be demonstrated. Nevertheless, the original seminal observa- ultraviolet illumination with ethidium bromide.
tion of the association of hypermethylation with aging (Issa et
al., 1994) is thus reinforced, as it represented the first description Methylation-sensitive amplified fragment length
polymorphism (MS-AFLP)of a phenomenon that seems to reach vast and deep ramifica-
MS-AFLP was performed as described previously (Yamamoto et al., 2001)tions. The task ahead is to find the mechanistic links between
with slight modifications. Briefly, 1 g of genomic DNA was digested over-epigenetics, aging, and cancer unveiled by these recent studies.
night with 5 units of methylation-sensitive restriction endonuclease NotI
Notwithstanding the importance of the disruption of the epige- (Roche, Indianapolis, Indiana) and 2 units of methylation-insensitive MseI
netic code for cancer development, our studies show that, re- (NE Biolabs, Beverly, Massachusetts) at 37C. Two pairs of oligonucleotides
garding the neoplastic phenotype, genetics transcends epige- were annealed overnight at 37C to generate NotI (5-CTCGTAGACTGCG
TAGG-3 and 5-GGCCCCTACGCAGTCTAC-3) and MseI (5-GACGATnetics.
GAGTCCTGAG-3 and 5-TACTCAGGACTCAT-3) specific adaptors. The
digested DNA was ligated to 1.25 l each of 5 pmol/l NotI and 50 pmol/Experimental procedures
l MseI adaptor using 1 unit of T4 DNA ligase (Roche) overnight at 16C. A
primer complementary to the NotI adaptor (NotI primer, 5-GACTGCGDNA preparation and MSI screening
TAGGGGCCGCG-3) was labeled at the 5 end using 32P-	ATP (NEN) and T4Surgically removed frozen tissues of colorectal cancers and paired adjacent
polynucleotide kinase (Promega, Madison, Wisconsin). The adaptor-ligatednoncancerous tissue were obtained from the Cooperative Human Tissue
template DNA was amplified by PCR using the 32P-labeled NotI primer andNetwork. The tumors analyzed represent a random subgroup of 207 tumors
not-labeled MseI primer (5-GATGAGTCCTGAGTAAC-3). A total of 20 lfrom a consecutive collection of over 700 unselected colorectal cancers.
PCR mixture contained 6 ng of 32P-labeled NotI primer, 30 ng of MseI primer,Genomic DNA was prepared by standard phenol-chloroform extraction and
0.4 mM dNTP, and 1 unit of AmpliTaq DNA polymerase (Perkin-Elmer, Fosterethanol precipitation. Radioactive PCR using 32P-
dCTP (NEN-life Science
City, California) and 5 to 15 ng of template DNA. The PCR started at 72CProducts, Boston, Massachusetts) was carried out to analyze MSI as de-
for 30 s, 94C for 30 s, then followed by 35 cycles of 94C for 30 s, 52Cscribed previously (Yamamoto et al., 1999). Microsatellite status was deter-
for 30 s, and 72C for 2 min. The final extension was performed for 10mined using two mononucleotide markers (BAT-26 and AP3) and one
min at 72C. Each PCR sample was electrophoresed on a denaturing geldinucleotide marker (D1S158). Tumors with deletion of multiple repeat units
(Sequagel-6, National Diagnostics, Atlanta, Georgia) after heat denaturing.in any of the two mononucleotide loci were defined as MMP positive, al-
The gel was dried on a gel drier and exposed to an X-ray film.though the vast majority of MMP-positive cancers exhibited mutation in both
the two mononucleotide markers as well as the dinucleotide marker (see
Figure 3C). This analysis classified the tumors into 28 (14%) MMP-positive, Scoring of methylation alteration in tumors by MS-AFLP
The sensitivity of MS-AFLP is highly dependent on the degree of normaland 154 (75%) MMP-negative. MMP-positive tumors in our classification
(Rampino et al., 1997; Perucho, 1999) correspond to MSI-H tumors in the tissue contamination in the tumor specimens. A considerable amount of
normal cells in the tumor sample may obscure the intensity differences. WeBethesda classification (Boland et al., 1998). In addition, 22 (11%) displayed
sporadic alterations (deletion or insertion of one or two repeat units) only in were able to approximately estimate the contamination level in MSI-positive
samples from the autoradiographs of BAT-26 and other mononucleotidethe dinucleotide repeat. A subset of the cancers was analyzed with additional
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Chan, A.O.O., Issa, J.P.J., Morris, J.S., Hamilton, S.R., and Rashid, A. (2002).repeats as described previously (Suzuki et al., 2002). To evaluate the contam-
Concordant CpG island methylation in hyperplastic polyposis. Am. J. Pathol.ination level in MSI-negative cases, LOH analysis using 5–7 polymorphic
160, 529–536.dinucleotide markers was conducted prior to MS-AFLP. Samples showing
a LOH pattern with the band corresponding to the lost allele with an intensity
Eads, C.A., Lord, R.V., Wichramasinghe, K., Long, T.I., Kurumboor, S.K.,
less than 25% of the band corresponding to the retained allele at any marker
Bernstein, L., Peters, J.H., DeMeester, S.R., DeMeester, T.R., Skinner, K.A.,
were regarded as adequate for MS-AFLP analysis. and Laird, P.W. (2001). Epigenetic patterns in the progression of esophageal
Only major bands in the fingerprints were considered for the assessment adenocarcinoma. Cancer Res. 61, 3410–3418.
of methylation alterations. Scoring of quantitative changes between normal
and tumor DNA were made by visual inspection as described previously Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003). Chromosomal
(Yamamoto et al., 2001). Scoring of signal intensity changes was done by instability and tumors promoted by DNA hypomethylation. Science 300, 455.
two observers independently. Only commonly detected alterations by the
Elsaleh, H., Joseph, D., Grieu, F., Zeps, N., Spry, N., and Iacopetta, B.two independent investigators were considered for the analysis. Further-
(2000). Association of tumour site and sex with survival benefit from adjuvantmore, only changes commonly detected in at least two independent finger-
chemotherapy in colorectal cancer. Lancet 355, 1745–1750.prints with duplicates of DNA from normal and tumor tissue were included.
Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B., and Herman, J.G.
DNA sequencing (1999). Inactivation of the DNA repair gene O6-methylguanine-DNA methyl-
Bands showing intensity alterations in MS-AFLP fingerprints were excised transferase by promoter hypermethylation is a common event in primary
from the gels and subjected to a second round PCR using the same primer human neoplasia. Cancer Res. 59, 793–797.
pair. After column-purification (QIAquick PCR purification kit, Qiagen, Valen-
Esteller, M., Corn, P.G., Baylin, S.B., and Herman, J.G. (2001). A genecia, California), the PCR products were directly sequenced using ABI Prism
hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229.BigDye Terminator Cycle Sequence Ready Reaction Kit and a DNA se-
quencer (Perkin-Elmer). The sequences were subjected to a BLAST search Feinberg, A.P., and Vogelstein, B. (1983). Hypomethylation distinguishes
to identify their origins in the human genome. genes of some human cancers from their normal counterparts. Nature 301,
89–92.
Comparison of MS-AFLP with MS-PCR
Gardiner-Garden, M., and Frommer, M. (1987). CpG islands in vertebrateTo contrast the sensitivity and specificity of the two methods, one of the
genomes. J. Mol. Biol. 196, 261–282.MS-AFLP bands showing methylation alterations was isolated, and the char-
acterized CpG island containing the NotI site (ACG) was further analyzed
Graff, J.R., Herman, J.G., Myohanen, S., Baylin, S.B., and Vertino, P.M.by MS-PCR in parallel to the six loci examined in the panel of 206 tumors.
(1997). Mapping patterns of CpG island methylation in normal and neoplasticThe results showed an 85% concordance between MS-AFLP and MS-PCR.
cells implicates both upstream and downstream regions in de novo methyla-
The same tumors that exhibited tumor-specific hypermethylation of the ACG
tion. J. Biol. Chem. 272, 22322–22329.
sequence by MS-AFLP also showed hypermethylation in tumor tissue by
MS-PCR. Hawkins, N., Norrie, M., Cheong, K., Mokany, E., Ku, S.L., Meagher, A.,
O’Connor, T., and Ward, R. (2002). CpG island methylation in sporadic
Acknowledgments colorectal cancers and its relationship to microsatellite instability. Gastroen-
terology 122, 1376–1387.
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